Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFARY: Empagliflozin in Type 2 Diabetes patients undergoing PCI
NCT04497792Phase 4Completed
- Sponsor
- Research Institute for Complex Problems of Cardiovascular Diseases
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Research Institute for Complex Problems of Cardiovascular Diseases. Started Nov 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04497792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497792.